Circulating tumor DNA: clinical roles in diffuse large B cell lymphoma

Area of Science:

• Oncology
• Molecular Biology
• Hematology

Background:

• Diffuse Large B cell Lymphoma (DLBCL) is a heterogeneous non-Hodgkin lymphoma (NHL).
• Accurate genetic profiling is crucial for personalized medicine in DLBCL, but obtaining tumor tissue is often challenging.
• Current diagnostic and monitoring methods for DLBCL have limitations.

Purpose of the Study:

• To review recent advancements in the use of circulating tumor DNA (ctDNA) for DLBCL.
• To discuss the clinical utility of ctDNA in DLBCL management compared to existing methods.
• To highlight the potential of ctDNA in facilitating precision medicine for DLBCL patients.

Main Methods:

• Literature review of recent studies on ctDNA in DLBCL.
• Comparative analysis of ctDNA with current routine diagnostic and monitoring techniques.
• Discussion of ctDNA's role at various stages of DLBCL disease course.

Main Results:

• ctDNA analysis provides a noninvasive, real-time, and tumor-specific biomarker for DLBCL.
• ctDNA reliably reflects comprehensive tumor genetic profiles and disease dynamics.
• ctDNA demonstrates significant potential in precise diagnosis, prognosis, response monitoring, and relapse detection.

Conclusions:

• ctDNA is a promising biomarker for overcoming challenges in DLBCL genomic profiling.
• ctDNA holds great potential for individualized medicine in DLBCL.
• ctDNA is anticipated to be integrated into DLBCL management for enhanced precision medicine.